PTCH1 is altered in 16.77% of medulloblastoma patients [3].

PTCH1 is an inclusion criterion in 9 clinical trials for medulloblastoma, of which 8 are open and 1 is closed. Of the trials that contain PTCH1 status and medulloblastoma as inclusion criteria, 2 are phase 1 (2 open), 3 are phase 1/phase 2 (2 open), 3 are phase 2 (3 open), and 1 is phase 4 (1 open) [4].

PTCH1 is altered in 3.0% of malignant solid tumor patients [3].

PTCH1 is an inclusion criterion in 4 clinical trials for malignant solid tumor, of which 3 are open and 1 is closed. Of the trials that contain PTCH1 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (0 open) and 3 are phase 2 (3 open) [4].

PTCH1 is an inclusion criterion in 4 clinical trials for medulloblastoma, non-WNT/non-SHH, of which 4 are open and 0 are closed. Of the trials that contain PTCH1 status and medulloblastoma, non-WNT/non-SHH as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 2 (1 open), and 1 is phase 4 (1 open) [4].

PTCH1 is altered in 81.03% of basal cell carcinoma patients [3].

PTCH1 is an inclusion criterion in 3 clinical trials for basal cell carcinoma, of which 2 are open and 1 is closed. Of the trials that contain PTCH1 status and basal cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (1 open) [4].

PTCH1 is altered in 37.5% of desmoplastic/nodular medulloblastoma patients [3].

PTCH1 is an inclusion criterion in 2 clinical trials for desmoplastic/nodular medulloblastoma, of which 2 are open and 0 are closed. Of the trials that contain PTCH1 status and desmoplastic/nodular medulloblastoma as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 4 (1 open) [4].

PTCH1 is altered in 13.48% of central nervous system embryonal neoplasm patients [3].

PTCH1 is an inclusion criterion in 2 clinical trials for central nervous system embryonal neoplasm, of which 2 are open and 0 are closed. Of the trials that contain PTCH1 status and central nervous system embryonal neoplasm as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [4].

PTCH1 is altered in 5.54% of melanoma patients [3].

PTCH1 is an inclusion criterion in 2 clinical trials for melanoma, of which 1 is open and 1 is closed. Of the trials that contain PTCH1 status and melanoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [4].

PTCH1 is altered in 3.65% of glioblastoma patients [3].

PTCH1 is an inclusion criterion in 2 clinical trials for glioblastoma, of which 1 is open and 1 is closed. Of the trials that contain PTCH1 status and glioblastoma as inclusion criteria, 2 are phase 1 (1 open) [4].

PTCH1 is altered in 2.76% of non-small cell lung carcinoma patients [3].

PTCH1 is an inclusion criterion in 2 clinical trials for non-small cell lung carcinoma, of which 1 is open and 1 is closed. Of the trials that contain PTCH1 status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [4].

PTCH1 is altered in 3.16% of bladder carcinoma patients [3].

PTCH1 is an inclusion criterion in 2 clinical trials for bladder carcinoma, of which 1 is open and 1 is closed. Of the trials that contain PTCH1 status and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [4].

PTCH1 is altered in 2.55% of anaplastic astrocytoma patients [3].

PTCH1 is an inclusion criterion in 2 clinical trials for anaplastic astrocytoma, of which 1 is open and 1 is closed. Of the trials that contain PTCH1 status and anaplastic astrocytoma as inclusion criteria, 2 are phase 1 (1 open) [4].

PTCH1 is altered in 1.59% of pancreatic carcinoma patients [3].

PTCH1 is an inclusion criterion in 2 clinical trials for pancreatic carcinoma, of which 1 is open and 1 is closed. Of the trials that contain PTCH1 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [4].

PTCH1 is an inclusion criterion in 2 clinical trials for central nervous system ganglioneuroblastoma, of which 2 are open and 0 are closed. Of the trials that contain PTCH1 status and central nervous system ganglioneuroblastoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [4].

PTCH1 is an inclusion criterion in 2 clinical trials for central nervous system neuroblastoma, of which 2 are open and 0 are closed. Of the trials that contain PTCH1 status and central nervous system neuroblastoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [4].

PTCH1 is an inclusion criterion in 2 clinical trials for large cell/anaplastic medulloblastoma, of which 2 are open and 0 are closed. Of the trials that contain PTCH1 status and large cell/anaplastic medulloblastoma as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 4 (1 open) [4].

PTCH1 is an inclusion criterion in 2 clinical trials for medulloblastoma with extensive nodularity, of which 2 are open and 0 are closed. Of the trials that contain PTCH1 status and medulloblastoma with extensive nodularity as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 4 (1 open) [4].

PTCH1 is an inclusion criterion in 2 clinical trials for medulloblastoma, SHH-activated, of which 2 are open and 0 are closed. Of the trials that contain PTCH1 status and medulloblastoma, SHH-activated as inclusion criteria, 2 are phase 1 (2 open) [4].

PTCH1 is an inclusion criterion in 2 clinical trials for medulloblastoma, WNT-activated, of which 2 are open and 0 are closed. Of the trials that contain PTCH1 status and medulloblastoma, WNT-activated as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].

PTCH1 is an inclusion criterion in 2 clinical trials for medulloepithelioma, of which 2 are open and 0 are closed. Of the trials that contain PTCH1 status and medulloepithelioma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [4].

PTCH1 is altered in 9.09% of pineoblastoma patients [3].

PTCH1 is an inclusion criterion in 1 clinical trial for pineoblastoma, of which 1 is open and 0 are closed. Of the trial that contains PTCH1 status and pineoblastoma as inclusion criteria, 1 is phase 4 (1 open) [4].

PTCH1 is altered in 5.0% of anaplastic pleomorphic xanthoastrocytoma patients [3].

PTCH1 is an inclusion criterion in 1 clinical trial for anaplastic pleomorphic xanthoastrocytoma, of which 1 is open and 0 are closed. Of the trial that contains PTCH1 status and anaplastic pleomorphic xanthoastrocytoma as inclusion criteria, 1 is phase 1 (1 open) [4].

PTCH1 is altered in 4.97% of anaplastic oligodendroglioma patients [3].

PTCH1 is an inclusion criterion in 1 clinical trial for anaplastic oligodendroglioma, of which 1 is open and 0 are closed. Of the trial that contains PTCH1 status and anaplastic oligodendroglioma as inclusion criteria, 1 is phase 1 (1 open) [4].

PTCH1 is altered in 3.51% of anaplastic ependymoma patients [3].

PTCH1 is an inclusion criterion in 1 clinical trial for anaplastic ependymoma, of which 1 is open and 0 are closed. Of the trial that contains PTCH1 status and anaplastic ependymoma as inclusion criteria, 1 is phase 1 (1 open) [4].

PTCH1 is altered in 4.85% of colorectal carcinoma patients [3].

PTCH1 is an inclusion criterion in 1 clinical trial for colorectal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains PTCH1 status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

PTCH1 is altered in 3.26% of high-grade glioma, NOS patients [3].

PTCH1 is an inclusion criterion in 1 clinical trial for high-grade glioma, NOS, of which 1 is open and 0 are closed. Of the trial that contains PTCH1 status and high-grade glioma, NOS as inclusion criteria, 1 is phase 1 (1 open) [4].

PTCH1 is altered in 3.57% of malignant glioma patients [3].

PTCH1 is an inclusion criterion in 1 clinical trial for malignant glioma, of which 1 is open and 0 are closed. Of the trial that contains PTCH1 status and malignant glioma as inclusion criteria, 1 is phase 1 (1 open) [4].

PTCH1 is altered in 3.4% of diffuse glioma patients [3].

PTCH1 is an inclusion criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains PTCH1 status and diffuse glioma as inclusion criteria, 1 is phase 1 (1 open) [4].

PTCH1 is altered in 2.62% of head and neck carcinoma patients [3].

PTCH1 is an inclusion criterion in 1 clinical trial for head and neck carcinoma, of which 0 are open and 1 is closed. Of the trial that contains PTCH1 status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

PTCH1 is altered in 1.96% of diffuse midline glioma, H3 K27M-mutant patients [3].

PTCH1 is an inclusion criterion in 1 clinical trial for diffuse midline glioma, H3 K27M-mutant, of which 1 is open and 0 are closed. Of the trial that contains PTCH1 status and diffuse midline glioma, H3 K27M-mutant as inclusion criteria, 1 is phase 1 (1 open) [4].

PTCH1 is altered in 1.9% of multiple myeloma patients [3].

PTCH1 is an inclusion criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains PTCH1 status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [4].

PTCH1 is altered in 1.8% of breast carcinoma patients [3].

PTCH1 is an inclusion criterion in 1 clinical trial for breast carcinoma, of which 0 are open and 1 is closed. Of the trial that contains PTCH1 status and breast carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

PTCH1 is altered in 1.97% of ovarian carcinoma patients [3].

PTCH1 is an inclusion criterion in 1 clinical trial for ovarian carcinoma, of which 0 are open and 1 is closed. Of the trial that contains PTCH1 status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

PTCH1 is altered in 1.82% of sarcoma patients [3].

PTCH1 is an inclusion criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains PTCH1 status and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [4].

PTCH1 is altered in 1.31% of B-cell non-hodgkin lymphoma patients [3].

PTCH1 is an inclusion criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains PTCH1 status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

PTCH1 is altered in 1.24% of malignant salivary gland neoplasm patients [3].

PTCH1 is an inclusion criterion in 1 clinical trial for malignant salivary gland neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PTCH1 status and malignant salivary gland neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

PTCH1 is altered in 1.27% of lymphoma patients [3].

PTCH1 is an inclusion criterion in 1 clinical trial for lymphoma, of which 0 are open and 1 is closed. Of the trial that contains PTCH1 status and lymphoma as inclusion criteria, 1 is phase 1 (0 open) [4].

PTCH1 is altered in 1.14% of biliary tract carcinoma patients [3].

PTCH1 is an inclusion criterion in 1 clinical trial for biliary tract carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PTCH1 status and biliary tract carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

PTCH1 is an inclusion criterion in 1 clinical trial for anaplastic astrocytoma, IDH-mutant, of which 1 is open and 0 are closed. Of the trial that contains PTCH1 status and anaplastic astrocytoma, IDH-mutant as inclusion criteria, 1 is phase 1 (1 open) [4].

PTCH1 is an inclusion criterion in 1 clinical trial for anaplastic oligodendroglioma, IDH-mutant and 1p/19q-codeleted, of which 1 is open and 0 are closed. Of the trial that contains PTCH1 status and anaplastic oligodendroglioma, IDH-mutant and 1p/19q-codeleted as inclusion criteria, 1 is phase 1 (1 open) [4].

PTCH1 is an inclusion criterion in 1 clinical trial for atypical teratoid/rhabdoid tumor, of which 1 is open and 0 are closed. Of the trial that contains PTCH1 status and atypical teratoid/rhabdoid tumor as inclusion criteria, 1 is phase 1 (1 open) [4].

PTCH1 is an inclusion criterion in 1 clinical trial for embryonal tumor with multilayered rosettes, C19MC-altered, of which 1 is open and 0 are closed. Of the trial that contains PTCH1 status and embryonal tumor with multilayered rosettes, C19MC-altered as inclusion criteria, 1 is phase 1 (1 open) [4].

PTCH1 is an inclusion criterion in 1 clinical trial for embryonal tumor with multilayered rosettes, not otherwise specified, of which 1 is open and 0 are closed. Of the trial that contains PTCH1 status and embryonal tumor with multilayered rosettes, not otherwise specified as inclusion criteria, 1 is phase 1 (1 open) [4].

PTCH1 is altered in 1.35% of ependymoma patients [3].

PTCH1 is an inclusion criterion in 1 clinical trial for ependymoma, of which 1 is open and 0 are closed. Of the trial that contains PTCH1 status and ependymoma as inclusion criteria, 1 is phase 1 (1 open) [4].

PTCH1 is an inclusion criterion in 1 clinical trial for ependymoma, RELA fusion-positive, of which 1 is open and 0 are closed. Of the trial that contains PTCH1 status and ependymoma, RELA fusion-positive as inclusion criteria, 1 is phase 1 (1 open) [4].

PTCH1 is an inclusion criterion in 1 clinical trial for intracranial primitive neuroectodermal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PTCH1 status and intracranial primitive neuroectodermal neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].